Acute COPD exacerbation; This literature-non-study case was reported in a literature article and describes the occurrence of CHRONIC OBSTRUCTIVE PULMONARY DISEASE (Acute COPD exacerbation) in a 76-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Lung adenocarcinoma stage II (lung adenocarcinoma stage IIB on chemotherapy), Chronic obstructive pulmonary disease (underlying oxygen dependent severe COPD.), Hypoxic respiratory failure (chronic hypoxic respiratory failure), Non-Hodgkin's lymphoma (low grade non Hodgkin's lymphoma in remission), Hypertension, Gout and Hearing loss (hear failure).    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced CHRONIC OBSTRUCTIVE PULMONARY DISEASE (Acute COPD exacerbation) (seriousness criterion hospitalization prolonged). The patient was treated with PREDNISONE at an unspecified dose and frequency. At the time of the report, CHRONIC OBSTRUCTIVE PULMONARY DISEASE (Acute COPD exacerbation) was resolving.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body temperature: 102f (High) fever 102F. On an unknown date, Computerised tomogram: abnormal (abnormal) Contrast enhanced computed tomography (CT) of chest/abdomen/pelvis revealed known left lower lobe lesion which is decreased in size, without signs of pulmonary or abdominal infection.. On an unknown date, Echocardiogram: abnormal (abnormal) Echocardiogram was without signs of vegetation, with preserved ejection fraction.. On an unknown date, White blood cell count: normal (normal) Infectious workup was negative, which included normal WBC without left shift.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered CHRONIC OBSTRUCTIVE PULMONARY DISEASE (Acute COPD exacerbation) to be possibly related.    Patient presented with fever 102F and shortness of breath. Patient was in his usual state of health, undergoing last chemotherapy 3 weeks ago which he tolerated well. A day prior the admission patient received his 2nd dose of mRNA-1273 (Moderna COVID-19 vaccine). Within the next 24h patient developed fever and shortness of breath which brought him to the emergency department. On admission patient with obvious respiratory wheezing, for which he was treated with systemic steroids.  Patient was monitored off antibiotics. Fever and shortness of breath quickly improved with systemic steroids. Patient remained stable on his home dose of oxygen supplementation while inpatient, and was successfully discharged to home with prednisone taper.  Author concluded that the inflammatory response from receiving COVID-19 vaccine, can lead to acute exacerbation of COPD in certain high risk patients. Additional safety data is needed in post vaccine surveillance in this sub group of patients.  Company Comment: This is a literature case concerning a 78 year-old male patient with  medical history of Lung adenocarcinoma stage II, Chronic obstructive pulmonary disease, Hypoxic respiratory failure and Non-Hodgkin's lymphoma who experienced the serious unexpected event of CHRONIC OBSTRUCTIVE PULMONARY DISEASE one dat after receiving the second dose of  spikevax. Rechallenge was not applicable. Patient´s medical history mentioned above remains as confounders/co suspect for these events. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.   Most recent FOLLOW-UP information incorporated above includes: On 21-Oct-2021: Follow up received by safety on 21-Oct-2021 included an Email with FTA received from SARA team and does not contain any new information.; Sender's Comments: This is a literature case concerning a 78 year-old male patient with  medical history of Lung adenocarcinoma stage II, Chronic obstructive pulmonary disease, Hypoxic respiratory failure and Non-Hodgkin's lymphoma who experienced the serious unexpected event of CHRONIC OBSTRUCTIVE PULMONARY DISEASE one dat after receiving the second dose of  spikevax. Rechallenge was not applicable. Patient´s medical history mentioned above remains as confounders/co suspect for these events. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.